BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37703328)

  • 21. Simultaneous measurement of the size and methylation of chromosome 4qA-D4Z4 repeats in facioscapulohumeral muscular dystrophy by long-read sequencing.
    Hiramuki Y; Kure Y; Saito Y; Ogawa M; Ishikawa K; Mori-Yoshimura M; Oya Y; Takahashi Y; Kim DS; Arai N; Mori C; Matsumura T; Hamano T; Nakamura K; Ikezoe K; Hayashi S; Goto Y; Noguchi S; Nishino I
    J Transl Med; 2022 Nov; 20(1):517. PubMed ID: 36348371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Facioscapulohumeral Muscular Dystrophy.
    DeSimone AM; Pakula A; Lek A; Emerson CP
    Compr Physiol; 2017 Sep; 7(4):1229-1279. PubMed ID: 28915324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
    Gatica LV; Rosa AL
    Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allele-specific DNA hypomethylation characterises FSHD1 and FSHD2.
    Calandra P; Cascino I; Lemmers RJ; Galluzzi G; Teveroni E; Monforte M; Tasca G; Ricci E; Moretti F; van der Maarel SM; Deidda G
    J Med Genet; 2016 May; 53(5):348-55. PubMed ID: 26831754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammatory facioscapulohumeral muscular dystrophy type 2 in 18p deletion syndrome.
    Renard D; Taieb G; Garibaldi M; Maues De Paula A; Bernard R; Lagha N; Cristofari G; Vovan C; Chaix C; Lévy N; Khau Van Kien P; Sacconi S
    Am J Med Genet A; 2018 Aug; 176(8):1760-1763. PubMed ID: 30055030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A proteomics study identifying interactors of the FSHD2 gene product SMCHD1 reveals RUVBL1-dependent DUX4 repression.
    Goossens R; Tihaya MS; van den Heuvel A; Tabot-Ndip K; Willemsen IM; Tapscott SJ; González-Prieto R; Chang JG; Vertegaal ACO; Balog J; van der Maarel SM
    Sci Rep; 2021 Dec; 11(1):23642. PubMed ID: 34880314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Facioscapulohumeral muscular dystrophy: consequences of chromatin relaxation.
    van der Maarel SM; Miller DG; Tawil R; Filippova GN; Tapscott SJ
    Curr Opin Neurol; 2012 Oct; 25(5):614-20. PubMed ID: 22892954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD.
    Krom YD; Thijssen PE; Young JM; den Hamer B; Balog J; Yao Z; Maves L; Snider L; Knopp P; Zammit PS; Rijkers T; van Engelen BG; Padberg GW; Frants RR; Tawil R; Tapscott SJ; van der Maarel SM
    PLoS Genet; 2013 Apr; 9(4):e1003415. PubMed ID: 23593020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small noncoding RNAs in FSHD2 muscle cells reveal both DUX4- and SMCHD1-specific signatures.
    Lim JW; Wong CJ; Yao Z; Tawil R; van der Maarel SM; Miller DG; Tapscott SJ; Filippova GN
    Hum Mol Genet; 2018 Aug; 27(15):2644-2657. PubMed ID: 29741619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SMCHD1 and LRIF1 converge at the FSHD-associated D4Z4 repeat and LRIF1 promoter yet display different modes of action.
    Šikrová D; Testa AM; Willemsen I; van den Heuvel A; Tapscott SJ; Daxinger L; Balog J; van der Maarel SM
    Commun Biol; 2023 Jun; 6(1):677. PubMed ID: 37380887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DICER/AGO-dependent epigenetic silencing of D4Z4 repeats enhanced by exogenous siRNA suggests mechanisms and therapies for FSHD.
    Lim JW; Snider L; Yao Z; Tawil R; Van Der Maarel SM; Rigo F; Bennett CF; Filippova GN; Tapscott SJ
    Hum Mol Genet; 2015 Sep; 24(17):4817-28. PubMed ID: 26041815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-resolution breakpoint junction mapping of proximally extended D4Z4 deletions in FSHD1 reveals evidence for a founder effect.
    Lemmers RJLF; van der Vliet PJ; Granado DSL; van der Stoep N; Buermans H; van Schendel R; Schimmel J; de Visser M; van Coster R; Jeanpierre M; Laforet P; Upadhyaya M; van Engelen B; Sacconi S; Tawil R; Voermans NC; Rogers M; van der Maarel SM
    Hum Mol Genet; 2022 Mar; 31(5):748-760. PubMed ID: 34559225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monosomy 18p is a risk factor for facioscapulohumeral dystrophy.
    Balog J; Goossens R; Lemmers RJLF; Straasheijm KR; van der Vliet PJ; Heuvel AVD; Cambieri C; Capet N; Feasson L; Manel V; Contet J; Kriek M; Donlin-Smith CM; Ruivenkamp CAL; Heard P; Tapscott SJ; Cody JD; Tawil R; Sacconi S; van der Maarel SM
    J Med Genet; 2018 Jul; 55(7):469-478. PubMed ID: 29563141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy.
    Jones TI; King OD; Himeda CL; Homma S; Chen JC; Beermann ML; Yan C; Emerson CP; Miller JB; Wagner KR; Jones PL
    Clin Epigenetics; 2015; 7(1):37. PubMed ID: 25904990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Facioscapulohumeral muscular dystrophy.
    Tawil R
    Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Facioscapulohumeral muscular dystrophy type 2].
    Sacconi S; Desnuelle C
    Rev Neurol (Paris); 2013; 169(8-9):564-72. PubMed ID: 23969240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Optical Genome Mapping in Clinical Genetic Testing of Facioscapulohumeral Muscular Dystrophy.
    Kovanda A; Lovrečić L; Rudolf G; Babic Bozovic I; Jaklič H; Leonardis L; Peterlin B
    Genes (Basel); 2023 Nov; 14(12):. PubMed ID: 38136988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemizygosity for SMCHD1 in Facioscapulohumeral Muscular Dystrophy Type 2: Consequences for 18p Deletion Syndrome.
    Lemmers RJ; van den Boogaard ML; van der Vliet PJ; Donlin-Smith CM; Nations SP; Ruivenkamp CA; Heard P; Bakker B; Tapscott S; Cody JD; Tawil R; van der Maarel SM
    Hum Mutat; 2015 Jul; 36(7):679-83. PubMed ID: 25820463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.
    Greco A; Goossens R; van Engelen B; van der Maarel SM
    Clin Genet; 2020 Jun; 97(6):799-814. PubMed ID: 32086799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.
    Jia FF; Drew AP; Nicholson GA; Corbett A; Kumar KR
    Neuromuscul Disord; 2021 Nov; 31(11):1101-1112. PubMed ID: 34711481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.